The members of our executive management team possess decades of combined experience in drug discovery and clinical development, and several have been involved in bringing oncology drugs to market.
Susan M. Molineaux, Ph.D., Founder, President and Chief Executive Officer
Dr. Molineaux has served as our President, Chief Executive Officer and as a member of our board of directors since she co-founded Calithera in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix’s acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000, she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999, she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux currently serves as a member of the board of directors of Geron Corporation, a biopharmaceutical company, and Theravance Biopharma, Inc., a biopharmaceutical company. She also currently serves as a member of the board of directors of We Teach Science, a San Francisco Bay Area mentoring program for students in math and science, and served as a member of the board of directors of the California Life Sciences Association until March 2016. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University.
Eric B. Sjogren, Ph.D., Senior Vice President of Drug Discovery
Dr. Sjogren has served as our Senior Vice President of Drug Discovery since June 2010. Dr. Sjogren has over 25 years of experience in small molecule drug discovery in the pharmaceutical industry. Prior to joining Calithera, Dr. Sjogren was Vice President and Head of Medicinal Chemistry at Roche Palo Alto, LLC from 2003 through 2009, where he directed a small molecule drug discovery team in the areas of inflammation, virology, and central nervous systems disorders. Dr. Sjogren received a B.A. degree in Chemistry from the University of California, San Diego and a Ph.D. degree in Chemistry from Harvard University.
Mark K. Bennett, Ph.D., Senior Vice President of Research
Dr. Bennett has served as our Senior Vice President of Research since June 2010. From 2003 through 2009, Dr. Bennett was at Proteolix, Inc., most recently as Vice President of Research, where he led the research efforts in the discovery of carfilzomib, oprozomib, and PR-957. Dr. Bennett previously was Director of Cell Biology at Rigel Pharmaceuticals, Inc. and an Assistant Professor of Molecular and Cell Biology at the University of California, Berkeley. Dr. Bennett received a B.S. degree in Biochemistry and Biophysics from Oregon State University, a Ph.D. degree in Neuroscience from the California Institute of Technology, and completed postdoctoral fellowships at the European Molecular Biology Laboratory and Stanford University.
Christopher J. Molineaux, Ph.D., Senior Vice President of Development
Dr. Molineaux has served as our Senior Vice President of Development since April 2013. From 2010 to 2013, Dr. Molineaux served as President of INDStrat LLC, a consulting firm. From 2004 to 2009, Dr. Molineaux was Vice President of Development at Proteolix, where he led the team that developed carfilzomib (marketed as Krypolis) through the completion of Phase 2 clinical trials for accelerated approval in the United States for the treatment of refractory multiple myeloma. Previously, Dr. Molineaux led the oral anemia project team at FibroGen, Inc. and prior to that, led the team at Praecis that discovered and developed abarelix (marketed as Plenaxis), which was approved for the treatment of prostate cancer. Dr. Molineaux received a B.S. in Zoology from University of Maryland, College Park, a Ph.D. in Immunology and Infections Diseases from Johns Hopkins University, and completed his postdoctoral fellowship at the Uniformed Services University of the Health Sciences.
Curtis C. Hecht, Senior Vice President of Business and Corporate Development
Mr. Hecht is Senior Vice President of Business and Corporate Development. Prior to joining Calithera in April 2014, Mr. Hecht served as Vice President of Business Development at inVentiv Health, a global healthcare commercialization and consulting services company. Since 2011, he has also served as a Partner at DNA Ink, a life sciences business development and licensing firm. Prior to that, Mr. Hecht served in a number of roles at Hoffman La-Roche Inc., most recently as Global Alliance Director from and Director of Global Business Development. While at Roche, he managed the Roche-Genentech Joint Development and Operations Committee that oversaw the global development for Avastin, Herceptin, Rituxan, Tarceva, Perjeta, Erivedge, TDM1. He currently sits on the advisory board to Biocision, LLC. Mr. Hecht received a B.S. in Chemistry from California State University, Sacramento and an M.B.A. from Carnegie Mellon University.
Keith Orford, M.D., Ph.D., Senior Vice President of Clinical Development
Dr. Orford is Senior Vice President of Clinical Development. Prior to joining Calithera in January 2015, Dr. Orford was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit at GlaxoSmithKline (GSK) where he oversaw the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GSK, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. Previously, Dr. Orford was a Research Fellow and Instructor at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) where he completed clinical training in Internal Medicine as well as postdoctoral work studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation. Dr. Orford received his undergraduate, M.D. and Ph.D. degrees from Georgetown University.
Frank Parlati, Ph.D., Vice President of Research
Dr. Parlati joined Calithera in 2012 and currently serves as Vice President of Research. Prior to joining Calithera, Mr. Parlati was Founder and Senior Director of Biology at Cleave Biosciences, a biotechnology company, from 2011 to 2012. Prior to that, Dr. Parlati held various scientific roles at Caltech, Proteolix and Rigel Pharmaceuticals. Dr. Parlati received a B.S. in Chemistry from Concordia University, a Ph.D. in Biology from McGill University and completed his postdoctoral fellowship at Memorial Sloan-Kettering.
Stephanie Wong, Vice President of Finance
Ms. Wong joined Calithera as Vice President, Finance in April 2014. From 2009 to 2013 Ms. Wong was at SciClone Pharmaceuticals, a publicly traded, commercial-stage pharmaceutical company, most recently as Vice President, Finance and Controller. From 2008 to 2009 Ms. Wong was Senior Director, Finance at AcelRx Pharmaceuticals. From 2001 to 2008 Ms. Wong held various positions at Kosan Biosciences, a publicly traded biotechnology company until its acquisition by Bristol-Myers Squibb, most recently as Senior Director and Controller. Prior to that Ms. Wong worked as an audit manager at PricewaterhouseCoopers. Ms. Wong received a B.S. degree in Business Administration from the University of California, Berkeley and is a Certified Public Accountant in the State of California.
Jennifer McNealey, Vice President of Investor Relations and Strategy
Ms. McNealey is Vice President of Investor Relations and Strategy. Prior to joining Calithera in 2015, Ms. McNealey served as an advisor to biotechnology companies, and founded Laurient LLC, an independent research company focused on the biotechnology and pharmaceutical industries. Prior to founding Laurient LLC, Ms. McNealey served as a portfolio manager and biotechnology analyst at various firms, including Franklin Templeton, Amerindo Investment Advisors and Morgan Stanley Dean Witter Advisors. Ms. McNealey currently serves as a member of the board of directors of Enzon Pharmaceuticals, a biopharmaceutical company. Ms. McNealey has a B.A. and an M.H.A. from Cornell University.
Sam Whiting, M.D., Ph.D., Vice President of Clinical Development
Sam Whiting M.D., Ph.D. has served as our Vice President of Clinical Development since May 2016. Most recently, Dr. Whiting served as Vice President of Research and Clinical Development at Gradalis, Inc. Dr. Whiting previously was Senior Medical Director at VentiRx Pharmaceuticals, and prior to that was Medical Director at Oncothyreon Inc. where he worked on the clinical development of both small molecule and immune-oncology products. Previously Dr. Whiting served as Assistant Professor of Medical Oncology at the University of Washington, Assistant Member of Clinical Research at the Fred Hutchinson Cancer Research Center, and Clinical Head of Gastrointestinal Oncology at the Seattle Cancer Care Alliance, all in Seattle, WA. Dr. Whiting completed fellowship training in medical oncology at the Fred Hutchinson Cancer Research Center and his training in internal medicine under the ABIM Research Pathway at the University of Washington. Dr. Whiting received his M.D. and Ph.D. (microbiology) as part of the Medical Scientist Training Program at the University of Washington Medical Center and his BS with Honors in Chemistry from Lewis and Clark College.
Hagit Glickman, Ph.D., Head of People and Culture
Dr. Hagit Glickman has been with Calithera Biosciences since the company’s founding in June 2010. She has 20 years of experience in business and has served as an advisor to numerous biotech and pharmaceutical companies including Proteolix, NovaBay, Takeda, and Novartis. She has founded and been CEO of startup companies in the healthcare industry. Dr. Glickman has a B.A. degree in Psychology from the University of California, Irvine and a Ph.D. in Clinical Psychology from the Pacific Graduate School of Psychology in Palo Alto.